EHHADH Contributes to Cisplatin Resistance Through Regulation by Tumor-suppressive MicroRNAs in Bladder Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2021 Jan 12

PMID 33430801

Citations 15

Authors

Shunsuke Okamura

Hirofumi Yoshino

Kazuki Kuroshima

Masafumi Tsuruda

Yoichi Osako

Takashi Sakaguchi

Masaya Yonemori

Yasutoshi Yamada

Shuichi Tatarano

Masayuki Nakagawa

Hideki Enokida

Affiliations

Soon will be listed here.

Abstract

Background: Cisplatin-based chemotherapy is recommended as the primary treatment for advanced bladder cancer (BC) with unresectable or metastatic disease. However, the benefits are limited due to the acquisition of drug resistance. The mechanisms of resistance remain unclear. Although there are some reports that some molecules are associated with cisplatin resistance in advanced BC, those reports have not been fully investigated. Therefore, we undertook a new search for cisplatin resistance-related genes targeted by tumor suppressive microRNAs as well as genes that were downregulated in cisplatin-resistant BC cells and clinical BC tissues.

Methods: First, we established cisplatin-resistant BOY and T24 BC cell lines (CDDP-R-BOY, CDDP-R-T24). Then, Next Generation Sequence analysis was performed with parental and cisplatin-resistant cell lines to search for the microRNAs responsible for cisplatin resistance. We conducted gain-of-function analysis of microRNAs and their effects on cisplatin resistance, and we searched target genes comprehensively using Next Generation mRNA sequences.

Results: A total of 28 microRNAs were significantly downregulated in both CDDP-R-BOY and CDDP-R-T24. Among them, miR-486-5p, a tumor suppressor miRNA, was negatively correlated with the TNM classification of clinical BC samples in The Cancer Genome Atlas (TCGA) database. Transfection of miRNA-486-5p significantly inhibited cancer cell proliferation, migration, and invasion, and also improved the cells' resistance to cisplatin. Among the genes targeted by miRNA-486-5p, we focused on enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase (EHHADH), which is involved in the degradation of fatty acids. EHHADH was directly regulated by miRNA-486-5p as determined by a dual-luciferase reporter assay. Loss-of-function study using EHHADH si-RNA showed significant inhibitions of cell proliferation, migration, invasion and the recovery of cisplatin sensitivity.

Conclusion: Identification of EHHADH as a target of miRNA-486-5p provides novel insights into the potential mechanisms of cisplatin resistance in BC.

Citing Articles

LncRNA Gm35585 transcriptionally activates the peroxidase EHHADH against diet-induced fatty liver.

Jin M, Lu Q, Xia N, Fan X, Zhang Z, Huang X Exp Mol Med. 2025; .

PMID: 40082671 DOI: 10.1038/s12276-025-01420-5.

Development of a novel treatment based on PKMYT1 inhibition for cisplatin-resistant bladder cancer with miR-424-5p-dependent cyclin E1 amplification.

Fukumoto W, Okamura S, Tamai M, Arima J, Kawahara I, Fukuda I BMC Cancer. 2024; 24(1):1333.

PMID: 39472827 PMC: 11523841. DOI: 10.1186/s12885-024-13109-5.

LncRNA BCYRN1 as a Potential Therapeutic Target and Diagnostic Marker in Serum Exosomes in Bladder Cancer.

Arima J, Yoshino H, Fukumoto W, Kawahara I, Saito S, Li G Int J Mol Sci. 2024; 25(11).

PMID: 38892143 PMC: 11172611. DOI: 10.3390/ijms25115955.

Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine- and cisplatin-resistant models.

Kawahara I, Yoshino H, Fukumoto W, Arima J, Saito S, Li G Mol Oncol. 2024; 18(9):2196-2211.

PMID: 38874588 PMC: 11467791. DOI: 10.1002/1878-0261.13684.

Serum EZH2 is a novel biomarker for bladder cancer diagnosis and prognosis.

Li F, Wang P, Ye J, Xie G, Yang J, Liu W Front Oncol. 2024; 14:1303918.

PMID: 38476362 PMC: 10927824. DOI: 10.3389/fonc.2024.1303918.

References

Alanee S, Alvarado-Cabrero I, Murugan P, Kumar R, Nepple K, Paner G . Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder. World J Urol. 2018; 37(1):107-114. DOI: 10.1007/s00345-018-2421-5. View

Pectasides D, Pectasides M, Economopoulos T . Systemic chemotherapy in locally advanced and/or metastatic bladder cancer. Cancer Treat Rev. 2006; 32(6):456-70. DOI: 10.1016/j.ctrv.2006.07.004. View

Sugita S, Yoshino H, Yonemori M, Miyamoto K, Matsushita R, Sakaguchi T . Tumor‑suppressive microRNA‑223 targets WDR62 directly in bladder cancer. Int J Oncol. 2019; 54(6):2222-2236. DOI: 10.3892/ijo.2019.4762. View

Liu J, Bi J, Li Z, Li Z, Liu X, Kong C . miR‑214 reduces cisplatin resistance by targeting netrin‑1 in bladder cancer cells. Int J Mol Med. 2018; 41(3):1765-1773. DOI: 10.3892/ijmm.2018.3374. View

Klootwijk E, Reichold M, Helip-Wooley A, Tolaymat A, Broeker C, Robinette S . Mistargeting of peroxisomal EHHADH and inherited renal Fanconi's syndrome. N Engl J Med. 2014; 370(2):129-38. DOI: 10.1056/NEJMoa1307581. View

He J, Xiao B, Li X, He Y, Li L, Sun Z . MiR-486-5p Suppresses Proliferation and Migration of Hepatocellular Carcinoma Cells through Downregulation of the E3 Ubiquitin Ligase CBL. Biomed Res Int. 2020; 2019:2732057. PMC: 6949685. DOI: 10.1155/2019/2732057. View

Shen D, Pouliot L, Hall M, Gottesman M . Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012; 64(3):706-21. PMC: 3400836. DOI: 10.1124/pr.111.005637. View

Li P, Yang X, Cheng Y, Zhang X, Yang C, Deng X . MicroRNA-218 Increases the Sensitivity of Bladder Cancer to Cisplatin by Targeting Glut1. Cell Physiol Biochem. 2017; 41(3):921-932. DOI: 10.1159/000460505. View

Dasari S, Tchounwou P . Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014; 740:364-78. PMC: 4146684. DOI: 10.1016/j.ejphar.2014.07.025. View

10.

Ishida S, Lee J, Thiele D, Herskowitz I . Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002; 99(22):14298-302. PMC: 137878. DOI: 10.1073/pnas.162491399. View

11.

Byun S, Kim S, Choi H, Lee C, Lee E . Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities. BJU Int. 2005; 95(7):1086-90. DOI: 10.1111/j.1464-410X.2005.05472.x. View

12.

Riddell I . Cisplatin and Oxaliplatin: Our Current Understanding of Their Actions. Met Ions Life Sci. 2018; 18. DOI: 10.1515/9783110470734-007. View

13.

Carthew R, Sontheimer E . Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009; 136(4):642-55. PMC: 2675692. DOI: 10.1016/j.cell.2009.01.035. View

14.

Houten S, Denis S, Argmann C, Jia Y, Ferdinandusse S, Reddy J . Peroxisomal L-bifunctional enzyme (Ehhadh) is essential for the production of medium-chain dicarboxylic acids. J Lipid Res. 2012; 53(7):1296-303. PMC: 3371241. DOI: 10.1194/jlr.M024463. View

15.

Manandhar M, Boulware K, Wood R . The ERCC1 and ERCC4 (XPF) genes and gene products. Gene. 2015; 569(2):153-61. PMC: 4536074. DOI: 10.1016/j.gene.2015.06.026. View

16.

Nelson K, Weiss G . MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther. 2008; 7(12):3655-60. DOI: 10.1158/1535-7163.MCT-08-0586. View

17.

Wen H, Lee S, Zhu W, Lee O, Yun S, Kim J . Glucose-derived acetate and ACSS2 as key players in cisplatin resistance in bladder cancer. Biochim Biophys Acta Mol Cell Biol Lipids. 2018; 1864(3):413-421. DOI: 10.1016/j.bbalip.2018.06.005. View

18.

Salimian J, Baradaran B, Azimzadeh Jamalkandi S, Moridikia A, Ahmadi A . MiR-486-5p enhances cisplatin sensitivity of human muscle-invasive bladder cancer cells by induction of apoptosis and down-regulation of metastatic genes. Urol Oncol. 2020; 38(9):738.e9-738.e21. DOI: 10.1016/j.urolonc.2020.05.008. View

19.

Josue Ruiz E, Diefenbacher M, Nelson J, Sancho R, Pucci F, Chakraborty A . LUBAC determines chemotherapy resistance in squamous cell lung cancer. J Exp Med. 2019; 216(2):450-465. PMC: 6363428. DOI: 10.1084/jem.20180742. View

20.

Yang H, Kong W, He L, Zhao J, ODonnell J, Wang J . MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008; 68(2):425-33. DOI: 10.1158/0008-5472.CAN-07-2488. View